Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited has issued 1,215,476 fully paid ordinary shares following the exercise of vested options and performance rights, expanding its share capital on 8 April 2026. The company has applied for quotation of the new shares on the ASX and confirmed, via a cleansing notice, that the issue was conducted without a prospectus while remaining compliant with continuous disclosure and financial reporting obligations.
The secondary trading notice indicates there is no excluded information related to the new shares, signalling transparency for investors and facilitating immediate on-market trading once quotation is granted. The move reflects ongoing equity-based incentives for Artrya’s stakeholders as it advances commercialisation of its AI cardiac imaging platform, without signalling any undisclosed material changes to its operations or outlook.
The most recent analyst rating on (AU:AYA) stock is a Sell with a A$3.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on AI-powered solutions for the detection and management of coronary artery disease. Its proprietary Salix cloud platform analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians with near real-time, point-of-care assessment in key international markets.
Average Trading Volume: 507,531
Technical Sentiment Signal: Buy
Current Market Cap: A$494.8M
For an in-depth examination of AYA stock, go to TipRanks’ Overview page.